Francesca Zammarchi
Company: ADC Therapeutics
Job title: Head of Pharmacology
Seminars:
Live Discussion & Question Time 9:40 am
day: Day One
Novel Application of a CD25-Targeted, Pyrrolobenzodiazepine (PBD) Dimer-Based ADC as Immunotherapeutic Agent 9:00 am
Currently, ADCs are predominantly used to directly target antigen-positive tumour cells This presentation will provide proof-of-concept for a novel application of a CD25-targeted, PBD-based ADC as immunotherapeutic agent, since the main mode of action relies on the ADC directly targeting T regulatory immune cells, rather than tumour cells Additional data will be presented showing promising…Read more
day: Day One